KROS (Keros Therapeutics) FCF Margin %: -981.47% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KROS Keros Therapeutics Inc KROS
30 GF Score
Price $10.21
! 2 Warning Signs
View Full Analysis

What is Keros Therapeutics FCF Margin %?

Keros Therapeutics KROS -3.41% 30 FCF Margin % is -981.47% as of Mar. 2026. GuruFocus rates KROS with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 950 Biotechnology companies, Keros Therapeutics ranks worse than 59.26% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Keros Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-3.60 Mil. Keros Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.37 Mil. Therefore, Keros Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was -981.47%.

As of today, Keros Therapeutics's current FCF Yield % is -28.83%.

The historical rank and industry rank for Keros Therapeutics's FCF Margin % or its related term are showing as below:

KROS' s FCF Margin % Range Over the Past 10 Years
Min: -84087.42   Med: -238.49   Max: 68.25
Current: -175.56

During the past 8 years, the highest FCF Margin % of Keros Therapeutics was 68.25%. The lowest was -84087.42%. And the median was -238.49%.

KROS's FCF Margin % is ranked worse than
59.26% of 950 companies
in the Biotechnology industry
Industry Median: -81.28 vs KROS: -175.56

Keros Therapeutics FCF Margin % Related Terms

Keros Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Keros Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Keros Therapeutics FCF Margin % Chart

Keros Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial -314.29 0.00 -84,087.42 -4,585.92 43.41

Keros Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 76.03 -167.01 21.86 -7,123.64 -981.47

KROS vs CDXS, CAMP, VYGR: FCF Margin % Comparison

For the Biotechnology subindustry, Keros Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Keros Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keros Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Keros Therapeutics's FCF Margin % falls into.


KROS
30GF Score
Keros Therapeutics Inc KROS
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Keros Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Keros Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=105.954/244.061
=43.41 %

Keros Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-3.602/0.367
=-981.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -981.47% mean?
Keros Therapeutics (KROS) has a FCF Margin % of -981.47% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Keros Therapeutics and its competitors. According to the industry distribution chart, Keros Therapeutics ranks #563 out of 950 companies in the Biotechnology industry, placing it in the top 59.3%.
Is Keros Therapeutics' FCF Margin % too high?
Keros Therapeutics' current FCF Margin % is -981.47%. Based on the distribution chart, Keros Therapeutics ranks #563 out of 950 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Keros Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Keros Therapeutics' FCF Margin % compare to CDXS and CAMP?
According to the Biotechnology industry distribution chart, Keros Therapeutics ranks #563 out of 950 companies for FCF Margin %. This places Keros Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Keros Therapeutics and its competitors. Keros Therapeutics's current FCF Margin % is -981.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keros Therapeutics stock overvalued right now?
Keros Therapeutics (KROS) has a current FCF Margin % of -981.47%. The current FCF Margin % is -981.47%. Keros Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Keros Therapeutics (KROS), the current FCF Margin % is -981.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Keros Therapeutics Business Description

Address 1050 Waltham Street, Suite 302, Lexington, MA, USA, 02421
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
30GF Score

Get the complete analysis for KROS

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.21
Price